Life sciences business OptiBiotix Health plc (AIM: OPTI) has launched its SlimBiome-based GoFigure products on Amazon India, targeting the world's most populous nation and its growing consumer base.
India, with obesity rates at 40.3% and projected to have the largest medium-to-high income population by 2035, offers significant opportunities for weight management products.
GoFigure products will also remain available through Apollo Pharmacies, both in-store and online, as part of a multi-channel strategy to drive growth in high-potential markets. The Amazon launch coincides with a rebranding effort featuring more vibrant packaging and prominent Fossence branding, leveraging consumer trust in Tata's proprietary ingredient.
OptiBiotix, founded in 2012, develops microbiome-modifying compounds addressing obesity, cardiovascular health and diabetes. Its partnerships with over 20 global food and healthcare companies further enhance its position in the wellness market.
AMGEN announces Q3 2026 dividend
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Gilead Sciences mobilises remdesivir donation to support Ebola response in Uganda
INOVIO's oartner ApolloBio reports positive topline results from Phase 3 trial of VGX-3100
Lilly declares Q2 2026 dividend
Collegium to acquire AZSTARYS from Corium Therapeutics
CVS Health announces quarterly dividend of USD0.665 per share